Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Targacept (TRGT) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (27)	7/31/2007 8:39:38 AM
From: dr.praveen	Read Replies (1) \| Respond to of 40

The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation W J de Jonge1,2 and L Ulloa3,4 1. 1Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands 2. 2Sir William Dunn School of Pathology, University of Oxford, Oxford, UK 3. 3The Feinstein Institute for Medical Research, North Shore University Hospital, Manhasset, NY, USA 4. 4Laboratory of Surgical Science Research, MSB-F673, UMDNJ-University of Medicine of New Jersey, Newark, NJ, USA Correspondence: Dr WJ de Jonge, Department of Gastroenterology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam. The Netherlands. E-mails: w.j.dejonge@amc.nl or Mail@LuisUlloa.com Received 21 December 2006; Revised 28 February 2007; Accepted 27 March 2007; Published online 14 May 2007. nature.com